40
Views
13
CrossRef citations to date
0
Altmetric
Case Report

Use of etanercept in a patient with rheumatoid arthritis on hemodialysis

, &
Pages 293-295 | Received 05 Nov 2007, Accepted 06 Dec 2007, Published online: 02 Jan 2014

References

  • Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum. 2003;33:1–18.
  • Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348–65.
  • Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005; 57:1407–13.
  • Nakamura M, Sakemi T, Nagasawa K. Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol. 1999;26:1424–5.
  • Akiyama Y, Fujimaki T, Sakurai Y. Pharmacokinetics of sala-zosulfapyridine in a hemodialysis patient (in Japanese). Ryumachi. 2003;43:569–76.
  • Hamada K. The safety of actarit (mover) in hemodialysis patients with rheumatoid arthritis (in Japanese). Prog Med. 1997;17: 1652–7.
  • Kaizu K, Komine N, Uriu K, Ikeda M, Hashimoto 0, Eto S. Bucillamine may be an effective anti-rheumatic drug in patients with end-stage renal disease—a case report (in Japanese). J Jpn Soc Dial Ther. 1994;27:1505–10.
  • Matthey F, Perrett D, Greenwood RN, Baker LRI. The use of fi-penicillamine in patients with rheumatoid arthritis undergoing hemodialysis. Clin Nephrol. 1986;25:268–71.
  • Saisho K, Kurosawa 0, Fukanoki T, Hanafusa A, Tajima N. Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Mod Rheumatol. 2001;11:132–5.
  • Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemo-dialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36:75–7.
  • Gruber SA, Hewitt JM, Sorenson AL. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol. 1994;34: 859–64.
  • Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation. 1994;57: 483–9.
  • Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29:636–7.
  • Hammoudeh M. Infliximab treatment in a patient with rheuma-toid arthritis on haemodialysis. Rheumatology (Oxford). 2006; 45:357–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.